Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation, progression, and propagation, and also impact the responses of cancerous cells to treatments. Read more…
L’ingénieur(e) d’étude mettra au point des méthodes expérimentales permettant de développer un modèle tri-dimensionelle de tumeurs colorectales et de prostate avec la technologie Biomimesys développée par HCS Pharma. La technologie de culture BIOMIMESYS® 3D reproduit fidèlement le microenvironnement naturel des cellules d’un organe cible. Il est attendu un soutien conceptuel Read more…
When Tuesday, June 28, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, June 30, 2022 – 1PM (CEST) / 7PM (CST) / 8PM (JST) / 7AM (EST) Where Online, using zoom.us and live on Youtube What Solid tumors are associated with a modified microenvironment, Read more…
The Extracellular Matrix (ECM) is a major component of all the organs. This dynamic structure is involved not only in cell adhesion, but also in physiological processes, including cell differentiation, migration, and maturation, tissue homeostasis, biochemical signal retention and mediation, and growth factors’ retention. Moreover, the ECM can be abnormally Read more…
Increased ExtraCellular Matrix (ECM) stiffness is a common process in many cancers (Pickup et al, 2014). This process influences the behaviour of cancer cells in the tumour microenvironment. The accumulation of ECM in the stroma is mainly due to a high production of ECM molecules by TGF-β(Transforming Growth Factor-beta) -stimulated Read more…
Historically, cancer has been described as originating from modified cells, because of mutations impacting their growth, their differentiation and their way (not) to die. Now, it is widely acknowledged that the microenvironment surrounding these cells is involved in cancer initiation and progression. As explained in the article by Nia Munn Read more…
The extracellular matrix (ECM) is the non-cellular component of tissue. Its is mainly composed of structural and adhesion molecules, such as hyaluronic acid, collagene, proteoglycans, fibronectin, elastin, although its specific composition and structure vary between different tissues. It is a dynamic structure, which is involved not only in the cell Read more…
The extracellular matrix (ECM) is a non-cellular component of tissues and organs. It is mainly composed of structural elements (proteoglycans collagens, elastin) and cell adhesion proteins such as fibronectin and laminins. The ECM forms a complex structure with physical properties (elasticity, tensile and compression strength), which provides physical support for Read more…
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation and progression, and also impact the responses of cancerous cells to treatments. Made Read more…
The lung is a vital organ which allows gas exchanges between the external environment and the body. These gas exchanges take place in alveoli, formed by 2 cell types : pneumocytes I and II (Martinez et al., 2017). The alveolar wall is supported by a basal membrane mainly composed of collagen Read more…
In 2020, Nia et al. published in the journal Science a review entitled ‘Physical traits of cancer‘. In this article, the authors proposed 4 distinct physical traits of cancer linked to the biomechanical abnormalities observed in tumoral tissues : an enhanced solid stress (compression and tension), i.e. the mechanical forces Read more…
2D cell culture has been used for more than 100 years now, to keep cells outside of their original organism and to use them for different purposes. It is still widely used in research and early steps of the drug discovery process, and has allowed a bunch of discoveries so Read more…
As you might know, October is the Breast Cancer Awareness Month, an annual campaign to raise awareness about the impact of breast cancer. Research is the key tool to fight this disease and we are very happy to collaborate with amazing research teams in this fight. Since last year, our Read more…
We are very please to welcome Dr Isabelle Van Seuningen (Director of CANTHER laboratories & Director of ONCOLille Cancer Institute) and Dr Vincent Senez (Research Director CNRS/CANTHER Laboratory/ONCOLille Institute) in our serie of talk about the uses of BIOMIMESYS®. They explain why they use this technology on cancer research with Read more…
As part of their engineering studies at ISEN Lille for a master’s degree specialized in Bionanotechnologies, Robin and Orégane arrived in HCS Pharma in May 2021 for a 4-month internship. Their work in HCS Pharma follows a student project during which they designed and computationally simulated a microfluidic device capable Read more…
Have you missed our last webinar with Molecular Devices about 3D oncology models? In April, our project leader Elodie was talking about how to establish and image physiologically relevant 3D cancer in vitro models, using BIOMIMESYS Oncology as a surrogate for the tumoral extracellular matrix. Our product BIOMIMESYS® Oncology matrix Read more…
We are very happy to invite you to our next webinar about 3D cellular cancer models and our BIOMIMESYS® Oncology matrix which allows cancer cells to be cultured in a tumor-like environment, with the possibility to tune the composition and stiffness of the matrix. We will also share our best Read more…
It was a great pleasure to present our technology BIOMIMESYS for relevant 3D cell cultures, and its applications in oncology field in the frame of ONCOLille seminars. All the questions and discussions at the end of our presentation convinced us that BIOMIMESYS is of great interest to oncology researchers, in Read more…
We are pleased and proud to welcome Dr Philippe Manivet and Dr Anthony Trezeibre in our Scientific Advisory Board. We are developing new innovative projects with them around our BIOMIMESYS technology. Because our BIOMIMESYS technology is requested in different fields and we want to stay at the forefront of innovation, Read more…
Abstract The extracellular polysaccharide hyaluronan (HA) controls cell migration, differentiation and proliferation, and contributes to the invasiveness of human cancers. The roles of HA cell surface receptors and hyaluronidases (HAses) in this process are still controversial. In order to investigate their involvement in cancer pathogenesis, we developed a reticulated HA Read more…
A publication from R. Lane et al, described the use of Small extracellular vesicles (sEVs) reservoir as a biomarker for Glioblastoma tumor subtyping. In this publication Astrocytes, Glioblastoma cell lines, and Glioblastoma patient-derived stem cells were grown in BIOMIMESYS® hydroscaffold. Abstract Glioblastoma (GBM) is one of the most aggressive solid tumors for which treatment options Read more…
New results of growing of breast cancer (MCF7 and MCF7-sh-wisp2) cells in BIOMIMESYS® Adipose tissue as a relevant 3D in vitro model, using Keller–Segel PDE system to model chemotactical auto-organization of cells. Abstract Three-dimensional cultures of cells are gaining popularity as an in vitro improvement over 2D Petri dishes. In many such experiments, Read more…
HCS-Pharma is pleased to launch BIOMIMESYS® Liver and Oncology in ready-to-use 384-well plate format for screening applications. Adopt BIOMIMESYS® 3D cell culture systems and obtain more predictive in vitro models. You can find our presentations in PDF format for BIOMIMESYS® Liver for BIOMIMESYS® Oncology For more information, contact us at hello@biomimesys.com